CA-CROWN-BIOSCIENCE
28.3.2024 13:31:27 CET | Business Wire | Press release
Crown Bioscience, a global contract research organization (CRO) and a JSR Life Sciences company, will showcase significant contributions in preclinical and translational oncology research at the American Association for Cancer Research (AACR) 2024 meeting. Highlighting its latest research, the company will present ten posters covering a broad spectrum of data from the company's R&D program.
The data presented will cover a range of innovative techniques in oncology and immuno-oncology drug discovery and development. Posters featured at AACR include:
- The in-depth Characterization of Acute Myeloid Leukemia Patient-Derived Xenograft (PDX) Models with Hotspot Gene Mutations for Therapeutic Evaluation.
- The development of an Integrated Pipeline for Immuno-Oncology Drug Testing, using patient-derived tumor organoids with a reconstituted tumor microenvironment and fresh ex vivo patient tissue cultures, aiming to enhance therapeutic evaluation and drug development efficiency with translational patient-derived systems.
- The utilization of Large Panel Organoid Drug Testing Combined with Biomarker Analysis, set to deliver insights into mechanisms of action and boost efficiency within the drug development pipeline.
- Research on KRAS Inhibitors and PARP Inhibitor-Induced Resistant PDX Ovarian Cancer Models further expands on the knowledge base of drug resistance patterns in cancer while also assessing innovative therapeutic approaches for targeting mutated tumors, including combination therapy.
- SynAI, an adaptive AI-driven platform for in silico drug synergism screening, optimizes the exploration of compound interactions in early-stage cancer drug development.
- Magnetic Resonance Imaging and Bioluminescence Imaging for Evaluating Tumor Burden in Orthotopic Glioblastoma, merging digital technology with cancer research to forecast a new era of therapeutic strategy development.
Abstracts for all ten poster presentations can be found on a dedicated page, Crown Bioscience AACR posters 2024. Following the show, all will be available for download.
Attendees are encouraged to visit Booth #1717 to learn more about these studies and talk to Crown Bioscience’s scientists to gain deeper insights into the platforms and services on offer to advance oncology research.
About Crown Bioscience
Crown Bioscience, a JSR Life Sciences company, is a global Contract Research Organization (CRO) partnering with biotech and pharmaceutical companies to rapidly advance the discovery and development of oncology drugs. As the exclusive preclinical CRO providing tumor organoid services with the well-established Hubrecht Organoid Technology, we offer over 600 organoid models spanning 22 cancer indications. Furthermore, we have developed the world’s largest commercially available PDX collection. Our focus on helping our customers develop novel therapies aims to ensure that patients receive the right treatment at the right time. Founded in 2006, we have 13 facilities across the US, Europe, and Asia. For more information, please visit www.crownbio.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240328082232/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Clene Nanomedicine Partners with Veristat to Reduce Biostatistical Output Time by 80% for ALS New Drug Application12.11.2026 18:09:00 CET | Press release
Veristat’s InStat™ delivers submission-ready tables, listings, and figures (TLFs) in one week using validated statistical engines, shortening the critical path from database lock to submission VeristatTM, a global clinical research organization (CRO) and consultancy specializing in complex studies, announced that it has partnered with Clene Nanomedicine to cut the time to deliver biostatistical outputs for a pivotal ALS drug application submission by 80%. Veristat reduced the time from study data to validated tables, listings and figures (TLFs) from up to six weeks to just one week. Clene, a late-stage biotech company, leveraged Veristat’s recently launched InStat™ platform, the industry’s first zero-code, fully automated solution to accelerate clinical trial processes. Biostatistical TLFs sit on the critical path for submissions, yet most sponsors rely on antiquated processes that involve slow, manual workflows to produce them, making post-database lock one of the biggest bottlenecks
WHOOP Launches WHOOP Humans, the Most Verifiably Human Social Network12.11.2026 18:00:00 CET | Press release
New feature lets members follow friends and family, share performance and health insights, and celebrate life's moments together WHOOP, the human performance brand, today launched WHOOP Humans, a new feature that lets members follow friends and family, share fitness, health, and performance data they choose, and support each other's progress. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261112176779/en/ WHOOP Launches WHOOP Humans, the Most Verifiably Human Social Network For more than a decade, WHOOP has helped members better understand their own health and performance. Now, WHOOP Humans extends that experience beyond the individual, making it easier to celebrate achievements, encourage progress, and look out for the people who matter most. "In a world that's becoming increasingly artificial, we're building something deeply human,” said Will Ahmed, Founder and CEO of WHOOP. “This is the most verifiably human network ever
Integrated Hubs for Green Chemistry Research Aim to Transform How Chemicals and Materials Are Designed12.11.2026 17:00:00 CET | Press release
International network will investigate fundamental principles for creating safer, higher-performing chemicals and materials The Gordon and Betty Moore Foundation today announced four Integrated Research Hubs to explore new frontiers in chemical design, from materials that respond to their surroundings to molecules designed for safety from the start. Bringing together global researchers across institutions and disciplines, the hubs will investigate fundamental principles that could enable new capabilities in chemicals and materials while improving performance and protecting human health and the environment. The research priorities emerged through extensive engagement with the scientific community to identify the questions that could transform what chemistry can achieve. Each hub will connect researchers across institutions around one of four green chemistry focus areas: Safer molecular design: Led by The George Washington University, this hub will combine artificial intelligence and qua
Roquette Highlights Scalable Excipient and Capsule Solutions for Regional and Global Pharmaceutical Markets at CPHI India 202612.11.2026 16:00:00 CET | Press release
Helping pharmaceutical manufacturers accelerate the journey from formulation to market through deep technical expertise, meaningful innovation, close collaboration and global capabilities Roquette, a global leader in plant-based ingredients and a leading provider of pharmaceutical excipients, will showcase its comprehensive portfolio of excipient and capsule solutions at CPHI India 2026, Hall 1, Booth 1I12 from November 23 to 25, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261112803410/en/ Meet Roquette at CPHI India 2026, Hall 1, Booth 1I12 At the event, Roquette will demonstrate how it helps pharmaceutical manufacturers accelerate the journey from formulation to market with confidence. By combining technical expertise, trusted quality, meaningful innovation and close collaboration, Roquette helps customers address formulation, scale-up and manufacturing challenges across a broad range of pharmaceutical application
Tigo Energy and Google Cloud Pair AI-Powered Tools for Solar Installers and Utilities12.11.2026 15:00:00 CET | Press release
The collaboration combines Tigo software with Google’s Gemini models on Google Cloud to help automate installer and utility operations for distributed energy portfolios. Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo” or “Company”), a leading provider of intelligent solar and energy software solutions, today announced a collaboration with Google Cloud to develop AI-enabled operational workflows for solar installers and distributed energy portfolios. By making core Tigo data and software products available through Google Cloud, Tigo aims to deliver faster deployment, simplified data integration, and additional insights with Gemini. The resulting workflows will help installers, asset managers, and energy operators more easily identify issues, prioritize actions, and automate routine operational tasks across growing fleets of distributed energy systems. As solar and storage portfolios expand, energy businesses are increasingly responsible for managing more sites, more system data, and more custo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom